When exposed to prolonged stress, rats develop gastric ulceration, enhanced colon motility with depletion of its mucin content and signs of physiological and behavioral arousal. In this model, we tested whether antidepressants (fluoxetine and bupropion), anxiolytics (diazepam and buspirone) or the novel nonpeptide corticotropin-releasing hormone (CRH) type-1 receptor (CRH-R1) antagonist, antalarmin, modify these responses. Fluoxetine, bupropion, diazepam and antalarmin all suppressed stress-induced gastric ulceration in male SpragueDawley rats exposed to four hours of plain immobilization. Antalarmin produced the most pronounced anti-ulcer effect and additionally suppressed the stress-induced colonic hypermotility, mucin depletion, autonomic hyperarousal and struggling behavior. Intraperitoneal CRH administration reproduced the intestinal but not the gastric responses to stress while vagotomy antagonized the stress-induced gastric ulceration but not the intestinal responses. We conclude that brain CRH-R1 and vagal pathways are essential for gastric ulceration to occur in response to stress and that peripheral CRH-R1 mediates colonic hypermotility and mucin depletion in this model. Nonpeptide CRH-R1 antagonists may therefore be prophylactic against stress ulcer in the critically ill and therapeutic for other pathogenetically related gastrointestinal disorders such as peptic ulcer disease and irritable bowel syndrome.
Introduction
In addition to predisposing to mental illness and altering the endocrine milieu of the organism, stress frequently precipitates marked disturbance of visceral functions. The gastrointestinal tract is one of the most vulnerable viscera to aversive psychological stimuli. 1 Individual variability in responding to stress ranges from nausea and vomiting to abdominal pain and diarrhea. Severe stress of life-threatening conditions, eg shock, head trauma, myocardial infarction, may be associated with stress ulcer (SU) development; a potentially fatal condition whose pathophysiology is still obscure. 2 Less severe, prolonged stress has been implicated in the pathogenesis of peptic ulcer disease 3 and irritable bowel syndrome (IBS). 4 appear to be interrelated and to be associated with affective and anxiety disorders. 5, 6 Moreover, early life adversity is associated with more prevalence of mood and anxiety disorders 7, 8 as well as predisposition to gastric ulceration 9 and IBS 10 later in adulthood. In spite of the fact that these stress-related gastrointestinal (GI) disorders constitute the most common presentation in gastroenterology and primary care clinics, 11 our ability to treat them is still limited as their underlying pathophysiologic mechanisms remain to be deconvoluted. 12 Since its identification as a classic component of the stress response by Selye (1936) 1 and establishing it as a model of somatic consequences of stress by Brodie, 13 stress-induced gastric ulceration has been widely used in studying visceral responses to stress. This includes exploring protective mechanisms against stress by measuring their potential for preventing stress ulceration. The same model is also useful as a model of nonulcer dyspepsia and peptic ulcer, particularly in the context of their biopsychosocial nature, in man. 3, 14 Many researchers in the area of gastrointestinal drugs screen their new compounds in the stress-induced gas-tric ulcer model. 15 Even though for more than a decade the focus of the etiology of peptic ulcer shifted to helicobacter infection, many clinicians now believe that the role of Helicobacter pylori in the causation of peptic ulcer is no more than a partial one. 3, 16 Other equally important factors include genetic makeup and vulnerability to stress. [17] [18] [19] Moreover, a recent study has negated the involvement of H. pylori in stress ulcer bleeding in critically ill patients. 2 The pivotal role of the brain in the pathogenesis of stress-induced gastric mucosal damage has been well established. Increased vulnerability to depression 20 and anxiety 21 in experimental animals is paralleled with ulcer development. The same holds true for humans. 5, 22 Moreover, classic antidepressants 23, 24 and anxiolytics 25, 26 significantly reduce stress ulcer formation, perhaps to a greater extent than that seen with traditional therapies such as cimetidine and antacids. 27 Indeed, induction of gastric lesions in rodents by sociopsychological stress is useful as an experimental model to assess the anxiolytic activity of novel drugs and the anxiolytic potency of a drug may be predicted by its anti-ulcer effect. 28 While the role of corticotropin-releasing hormone (CRH) in mediating the stress-induced alteration of gastrointestinal secretory and motor responses is fairly established, [29] [30] [31] its role in the pathogenesis of stress ulcer has been debatable. 32, 33 CRH is a 41-amino acid peptide that was first isolated as the principal hypothalamic hormone that mobilizes the pituitary-adrenal responses to stress 34 and subsequently identified as a key player in the behavioral and autonomic responses to stress in rodents 35 and nonhuman primates. 36 Several studies have shown that both stress and central CRH administration decrease gastric acid secretion, gastric emptying, and small bowel transit while markedly enhancing large bowel transit. 29, 37 Moreover, immobilization stress of rats causes increased colonic mucin and prostaglandin E 2 secretion, increased colonic mucosal levels of cyclooxygenase-2 mRNA, and degranulation of colonic mast cells, which are antagonized by alpha-helical CRH 9-41, a non specific peptide CRH antagonist. 31 Central administration of peptide CRH receptor antagonists prevents the gastrointestinal secretory and motor responses elicited by either stress or exogenous CRH in a dose-dependent fashion. 30, 38 The clinical development of nonpeptide antagonists which cross the blood-brain barrier to reset brain CRH-R1 for the treatment of anxiety 40 and melancholic depression 41 is currently the focus of extensive research. We have recently reported that oral administration of antalarmin, a member of this novel family of drugs, attenuates neuroendocrine and behavioral responses to stress in primates. 36 Due to the significant overlap in the neural circuitry that mediates mental and gastrointestinal responses to stress, 39 we hypothesized that CRH-R1 plays a role in the pathogenesis of gastrointestinal injury and/or dysfunction during stress. The recent availability of non-peptide CRH-R1 antagonists enabled us to examine the role of CRH-R1 Molecular Psychiatry in an animal model that simultaneously reproduces features of stress ulcer 13 and IBS. 4 Antalarmin, N-butyl-N-ethyl-[2,5,6-trimethyl-7-(2,4,6 trimethylphenyl)-7H-pyrrolo [2,3-d] pyrimidin-4-yl] amine, is a selective CRH-R1 antagonist that penetrates the blood-brain barrier and suppresses neuroendocrine, autonomic and behavioral responses to stress in primates. 36 Other pyrrolopyrimidine compounds also exert anxiolytic effects 42 and suppress colon hypermotility 43 in rodents. The major advantage of nonpeptide antagonists is their potential clinical utility in humans. 44 As opposed to peptide antagonists that require direct injections into the brain to access central CRH receptors, antalarmin can neutralize CRH-R1 whether in the brain or in the periphery after oral administration. 36 Here we first conducted a dose-response study to examine the effects of antalarmin on stress-induced gastric ulceration in adult male Sprague-Dawley rats. To determine whether antalarmin's effects are due to moderating the activity of the stress neurocircuitry, we tested it against other known antidepressants (bupropion and fluoxetine) and anxiolytics (diazepam and buspirone). We chose the latter drugs for their nonclassic antidepressant effects and lesser anticholinergic activity. 45 In addition to scoring gastric ulceration, we evaluated colon specimens for mucin depletion and counted the stool pellets as an index of enhanced colon motility in response to stress. 46 Stress-induced enhancement of intestinal transit in the rat has been proposed as an animal model for irritable bowel syndrome. 4 Moreover, defecation scores have been long known as valid representatives of fearfulness and anxiety in rodents. 47 Plasma catecholamines and struggling behavior were included as indices of autonomic and behavioral arousal in this model.
Experimental procedures
was synthesized in our laboratory as previously described. 48 For intraperitoneal (IP) injections, antalarmin was dissolved in cremophor/ ethanol/ saline, 5:5:90 by volume, and injected (0.5 ml per animal) immediately after preparation. Diazepam (Roche Lab, Nutley, NJ, USA) was suspended in 0.5% carboxymethylcellulose and injected intramuscularly. 49 Buspirone (Sigma, St Louis, MO, USA), bupropion (Sigma) and fluoxetine (Tocris Cookson, Ballwin, MO, USA) were dissolved in saline, and all were injected as 0.5 ml per animal IP. For the dose response experiment, four animal groups were included into which antalarmin was injected at doses of 0, 15, 30 and 45 mg kg −1 . For the comparative study, six treatment groups were included: saline (0.5 ml rat ), 51 bupropion (30 mg kg), 52 and fluoxetine (10 mg kg
). 53 CRH (human/rat CRF; Peninsula Lab, San Carlos, CA, USA) was dissolved in saline and injected IP (0.5 ml rat 
Animal experiments
Adult male (200-250 g) Sprague-Dawley rats (Taconic Farms, Germantown, NY, USA) were housed under controlled conditions on a 12-h light/12-h dark cycle for an average of 1 week after arrival to the animal facility. Rats were housed 3 to a cage and provided with food and water ad libitum except for the last 24 h preceding the experiment, when they were individually housed in mesh bottom cages and deprived of food, but not water. In our experience, fasted rats develop stress ulcers more readily and consistently than non-fasted subjects, particularly if stress is applied in the afternoon. All experiments were started between the hours of 12:00 and 13:00 to minimize the influence of circadian rhythm on the parameters under investigation. Animal procedures were approved by the National Institute of Child Health and Human Development Animal Care and Use Committee and conducted with strict adherence to the National Institutes of Health Guidelines of Animal Use in Intramural Research.
Animals groups received half the dose of their drug intraperitoneally (IP) twice at −2 h and +2 h of starting immobilization in the dose response experiment. A pilot experiment showed better anti-ulcer responses if the drugs were administered in full doses twice at −24 and −2 h prior to immobilization (data not shown), and therefore this latter regimen was used for the comparative study. Subdiaphragmatic or sham vagotomy were performed 4 days prior to the experiment as previously described. 54, 55 Immobilization stress lasted for 4 h and was performed essentially as described by Brodie 13 with slight modification. Briefly, awake rats were placed in the prone position on specifically designed stainless steel plates equipped with semi-circular rings that prevent the animal from turning around to access its taped lower trunk and feet. The animal's struggling behavior was blindly scored for 5 min at the summits of immobilization hours 1, 2 and 3, according to a previously validated scale that scores one point for every act of jaw movement, body rolling, tail flipping or vocalization, with simultaneous acts counted as the sum of their individual components. 49 The three time point results were averaged and expressed as the struggling score per hour. Colonic motility was estimated by counting the number of fecal pellets expelled during the immobilization period. 29, 46 After the elapse of 4 h, rats were released from their restrainers and immediately guillotined. Trunk blood was collected in ice-chilled tubes and spun in a cooling centrifuge at 1000 × g to obtain plasma for the assay of epinephrine and norepinephrine by high performance liquid chromatography coupled with electrochemical detection as previously described. 36 A sagittal laparotomy was performed to collect stomachs and colonic segments 10 cm proximal to the anal orifice. The latter specimens were fixed in formalin, embedded in paraffin and stained with hematoxylin, eosin and alcian blue for histological estimation of mucin content. Briefly, 7-m sections perpendicular through the mucosa in an area containing 10 parallel aligned crypts were examined for the percentage of mucin-positive goblet cells to the total number of colonocytes lining the superficial half of the crypts epithelium as described previously. 46 Stomachs were washed in ice cold saline and opened along the greater curvature to wash the interior with phosphate buffered saline for scoring gastric ulcers as the sum of their cumulative length in mm per stomach with the aid of a magnifying lens and a micrometer. 56 All samples were coded and blindly scored. Because of the protective effect of food against SU, stomachs containing food remnants were excluded regardless of their ulcer scores.
Statistical analysis
ANOVA followed by post-hoc (Dunnett's Multiple Comparison) test was used to study the effects of different treatments on plasma catecholamines, stress ulcer, intestinal mucin, struggling and defecation scores. ANOVA post-test for linear trend was used to express the results of the dose-response study. On all occasions, a P level was considered statistically significant at two-tailed values of 0.05 or less. Statistical analysis and graphic presentations were aided by Prism version 3.0 for Macintosh (GraphPad, Ithaca, NY, USA).
Results
Figures 1a and 1b show the dose response effects of antalarmin on stress-induced gastric ulceration (SU). Antalarmin reduced SU scores in a dose-dependent fashion, namely from 12.63 ± 1.711 at 0 mg kg −1 to 2.000 ± 1.323 at 45 mg kg −1
. ANOVA post-test for linear trend showed a slope of −1.788 (R 2 = 0.539, P Ͻ0.001). In freely moving animals, none of the drugs significantly caused any significant change in gastric ulceration, colonic mucin or defecation scores as compared to saline treatment (data not shown), and therefore the effects of different drugs on the parameters under investigation during stress are only presented.
In saline-treated animals, exposure to immobilization stress precipitated gastric ulceration (from 0.125 ± 0.125 mm to 15.88 ± 2.463 mm, t = 5.41, P Ͻ 0.001), colonic mucin depletion (from 13.4 ± 2.73 to 4.625 ± 0.944, t = 3.03, P Ͻ 0.01), and elevation of plasma epinephrine (from 8.40 ± 2.22 to 21.11 ± 2.55 ng ml −1 , t = 3.76, P Ͻ 0.01 ) and norepinephrine (from 5.45 ± 1.278 to 10.23 ± 0.849 ng ml −1 , t = 3.243, P Ͻ 0.01) as compared to freely moving animals.
There were no significant differences between saline treatment and any of the vehicles used for drug dissolution during stress on stress ulceration, defecation scores, struggling, colonic mucin, plasma epinephrine or plasma norepinephrine (Table 1) , and therefore we used saline treatment as the control group.
The ability of antalarmin and other psychotropic drugs to reduce stress ulcer are shown in Figures 2a and 2b. Significant reductions of stress ulceration from 15.88 ± 2.463 mm were achieved by antalarmin (to 1.392 ± 0.664 mm, P Ͻ 0.01) followed by diazepam (to 1.833 ± 0.726 mm, P Ͻ 0.01), bupropion (to 4.429 ± Vehicle A used to dissolve antalarmin consisted of cremophor/ethanol/saline, 5:5:90 by volume, and injected (0.5 ml per animal) intraperitoneally. Vehicle B used for diazepam consisted of 0.5% carboxymethylcellulose and injected intramuscularly (0.5 ml per animal). The rest of the drugs were dissolved in saline and injected intraperitoneally (0.5 ml per animal). As apparent in the ANOVA comparison column, there were no significant differences among the different vehicles on any of the parameters under investigation.
1.706 mm, P Ͻ 0.01) and fluoxetine (to 7.438 ± 1.668 mm, P Ͻ 0.01). Buspirone did not significantly alter SU scores (to 11.36 ± 2.497 mm, P Ͼ 0.05). Both diazepam and antalarmin significantly inhibited bowel hypermotility, as indicated by the stool pellet output (from 12.13 ± 1.663 to 5.875 ± 1.072 SPO per 3 h, P Ͻ 0.05 by diazepam, and to 5.938 ± 0.972, P Ͻ 0.05 by antalarmin) (Figure 3a ), but only antalarmin (Figure 3b ) significantly increased colonic mucin during exposure to stress (from 4.625 ± 0.944 to 9.5 ± 1.195 mucin-positive colonocyte per 100 colonocytes, P Ͻ 0.01).
Figures 4a, 4b and 4c show the effects of antalarmin and other psychotropic medications on struggling scores, plasma epinephrine and norepinephrine, respectively. As demonstrated in Figure 4a , antalarmin (20 mg kg ) was as effective as diazepam (5 mg kg −1 ) in decreasing the score of struggling; from 25.0 ± 3.525 to 9.0 ± 2.591 (P Ͻ 0.001) and to 11.5 ± 3.065, P Ͻ 0.05), respectively. Buspirone (15.5 ± 3.157), bupropion (17.5 ± 3.541) and fluoxetine (30.0 ± 3.117) did not significantly reduce struggling behavior in this model (P Ͼ 0.05). Reductions of plasma epinephrine from 21.11 ± 2.55 ng ml −1 were achieved by buspirone (10.79 ± 0.651 ng ml −1 , P Ͻ 0.001) followed by diazepam (12.38 ± 1.143 ng ml , P Ͻ 0.01) followed by buspirone (6.29 ± 0.544 ng ml −1 , P Ͻ 0.05), then antalarmin (6.916 ± 0.463 ng ml −1 , P Ͻ 0.05). Non-significant changes were obtained with the antidepressants bupropion (9.532 ± 2.56 ng ml −1 , P Ͼ 0.05) and fluoxetine (13.22 ± 1.277 ng ml −1 , P Ͼ 0.05).
Compared to the saline-treated animals, intraperitoneal CRH did not significantly change the animals' stress ulcer scores in non-stressed subjects (from 0.167 ± 0.167 to 0.167 ± 0.167, t = 0.0, P = 0.50). However, it significantly resulted in increased colon motility (from 4.3 ± 0.925 to 9.4 ± 1.75 SPO per 3 h, t = 2.577, P Ͻ Molecular Psychiatry 0.05) (Figure 5a ) and mucin depletion (from 7.89 ± 1.07 to 3.98 ± 1.06 mucin-positive colonocyte per 100 colonocytes, t = 2.596, P Ͻ 0.05) (Figure 5b ). The effects of intraperitoneal CRH on stool pellet output were also abolished by antalarmin pretreatment (compared to the vehicle group, t = 0.068, P Ͼ 0.05), but were marginally affected by vagotomy or sham operation (compared to the vehicle group, t = 2.146 and 2.26, P = 0.07 and P = 0.06, respectively) ( Figure 5a ). The effects of intraperitoneal CRH on mucin content were abolished by antalarmin pretreatment (compared to the vehicle group, t = 0.546, P Ͼ 0.05) but were not significantly affected by vagotomy or sham operation (compared to the vehicle group, t = 4.181 and 3.06, P Ͻ 0.01 and P Ͻ 0.02, respectively) ( Figure 5b) . Figure 6 shows that compared to sham-operated rats, vagotomized animals expressed significantly lower SU scores in response to the same stressor (from 17.65 ± 3.85 to 3.86 ± 2.5, t = 3.048, P Ͻ 0.02), but their scores of stool pellet output and colonocyte mucin content were not statistically different (data not shown). CRH administration had no effect on SU in either shamoperated (t = 1.459, P Ͼ 0.05) or vagotomized subjects (t = 0.619, P Ͼ 0.05). On the other hand, antalarmin pretreatment further attenuated SU in the sham-operated animals (t = 3.473 and 1.17, P Ͻ0.01 and Ͼ 0.05, for the sham-operated and vagotomized rats respectively).
Discussion
Here we show that antalarmin not only reduced gastric ulcerogenesis in responses to stress in a dose-dependent fashion, but also attenuated autonomic and behavioral indices of arousal. The relatively new antidepressants, bupropion and fluoxetine, as well as diazepam also exerted significant effects in attenuating SU, supporting the notion that stress ulceration is a centrally mediated process 57 and that it is their psychotropic properties that contribute to their ulcerolytic effects. We used the relatively new antidepressants bupropion and fluoxetine that are virtually devoid of antihistaminic or anticholinergic actions to avoid the argument that antidepressants attenuated stress ulcer-ogenesis via blocking cholinergic or histaminergic receptors. 45 It is unlikely that antalarmin produced its protective effects by merely attenuating glucocorticoid responses to stress because we have previously found that metyrapone does not modify the severity of stress ulceration, at doses (40 mg kg −1 IM) that effectively interfere with glucocorticoid synthesis in the same model. The notion that stress ulceration is a centrally mediated phenomenon is further supported by the failure of peripherally administered CRH to produce SUlike lesions in non-stressed subjects. On the contrary, IP CRH reproduced colonic responses to stress; an effect that was abolished by antalarmin pretreatment, which is in line with previous studies. 29, 30, 59, 60 Moreover, we have observed that the effects of IP CRH were not significantly different between vagotomized and sham-vagotomized animals, which further supports the notion that the intestinal effects of IP CRH were mediated by peripheral mechanisms.
In spite of its known implication in virtually the entire cascade of the stress response 36 and the reproducibility of stress ulceration as a central component of the animals' responses to stress, 1 the role of CRH in the pathophysiology of stress ulcer has been controversial, 3, 61 with some studies reporting an ulcerogenic effect of centrally administered CRH 33 and others reporting attenuation of cold restraint-induced gastric mucosal lesions by the same treatment. 32, 62 The disagreement of our findings with the latter reports may be due to the different techniques utilized and their direct injections into the brain of excessive quantities of CRH (in the microgram range) considering its naturally occurring concentrations (being in the picogram range). 36 At such concentrations, CRH acts locally as a proinflammatory agent and to increase the permeability of physiological barriers; both factors can significantly confound the roles attributed to the endogenous peptide. 63 Because our focus is on stress ulceration, whose pathophysiology cannot be simply explained by the associated secretory and motor patterns, 55, 58 we chose not to collect data on gastric secretion and motility. Thus we avoided the trauma of laparotomy usually required to collect gastric secretion or contractility records. Moreover, the ability of antalarmin to cross the blood-brain barrier allowed us to avoid inflicting the trauma of intracerebroventricular injections to the animals. The efficacy of antalarmin to antagonize stress ulceration under these circumstances indicates that endogenous CRH, via its type-1 receptor, mediates gastric ulcerogenesis caused mostly by plain immobilization, rather than other confounding physical stressors. Moreover, such findings indicate the potential clinical utility of nonpeptide CRH antagonists for the treatment of stress ulcer in the critically ill and perhaps peptic ulcer disease and non-ulcer dyspepsia.
Vagotomy produced antalarmin-like ulcerolytic effects, which agrees with previous reports. 64 The vagus has been long implicated in mediating gastric damage in response to stress. 65 By virtue of its extensive projections to brain nuclei that participate in the neurocircuitry of stress, the vagal efferents are well positioned to mediate the gastric responses to stress. 66 Indeed, the stomach receives by far more vagal innervation (both afferent and efferent) than any other viscus. 67 Efferent vagal fibers contain a variety of neurotransmitters that could be ulcerogenic, eg TRH, serotonin and opiate peptides. 65, 68 Moreover, the vagus is essential for the maintenance of mast cells and enterochromaffin-like cells in the stomach. 54 The latter cells contain highly ulcerogenic substances as well. CRH is extensively distributed in the hypothalamus and limbic system nuclei that project to the dorsal motor nucleus of the vagus (DMV) and CRH containing nerve fibers are found in the DMV. 66, 67 The effects of antalarmin in attenuating colonic responses to stress were also marked. It significantly suppressed both colonic hypermotility and mucin depletion. This agrees with recently published studies Molecular Psychiatry that have utilized different paradigms 43, 46 Moreover, exogenous parenteral CRH reproduced the intestinal responses to stress, in agreement with previous studies. 30 This is of particular interest in the light of Fukudo's finding of induction of colon motility in both IBS patients and control subjects by CRH administered intravenously, with significantly greater motility indexes in IBS patients than in controls. Abdominal symptoms evoked by CRH in IBS patients lasted significantly longer than those in the controls in the same study. 69 In the light of Williams' hypothesis of the usefulness of enhanced bowel motility in response to restraint stress to model an important aspect of IBS, our findings here might suggest the potential clinical utility of CRH-R1 antagonists to combat IBS. 4 Vagotomy-on the other hand-did not alter the intestinal responses to stress in this paradigm, again suggesting that the site of antalarmin action in modulating colonic responses to stress is primarily peripheral. In the gut, antalarmin could have directly exerted its effects via a multiplicity of mechanisms. CRH-containing cells have been identified in the human, monkey, cat, and rat stomach and small intestine. 70, 71 Local production of CRH has been detected in normal human colon enterochromaffin cells. 72 In patients with ulcerative colitis, considerably enhanced expression of immunoreactive CRH in mucosal inflammatory cells has been reported. Intense staining with anti-CRH antibody was also shown in mucosal macrophages and CRH mRNA was found to be expressed in mucosal epithelial cells. 73 Binding and pharmacological studies have documented the presence of CRH binding sites in the circular smooth muscles of the guinea pig cecum. 74 CRH binding sites have also been detected in the myenteric neurons from the guinea-pig ileum, 74, 75 where it evokes prolonged depolarization in the majority of these neurons in association with augmented excitability. 75 In isolated distal rat colon preparations, CRH provokes a concentration-dependent increase of both mechanical and electrical peristaltic activity. 76 Urocortin belongs to the CRH family of peptides and CRH-R1 is primarily involved in mediating ) injected 24 and 2 h before the experiment on immobilization stress-induced gastric ulceration. As shown, stress ulceration was reduced to Ͻ 9% by antalarmin, 11.5% by diazepam, 28% by bupropion and 47% by fluoxetine. (b) The interior of the rats' stomachs after the same treatments. Animals groups (n = 6-12) received the same dose of their drug intraperitoneally twice at −24 h and −2 h of exposure to immobilization stress for 4 h followed by immediate termination and collection of trunk blood and stomachs. The latter were opened along the greater curvature and the sum of each stomach ulcer length (cumulative ulcer length) was measured with the aid of a magnifying lens and a micrometer. *P Ͻ 0.05, **P Ͻ 0.01. There was essentially no ulceration in freely moving animals whether or not they received any medication. ) on immobilization stress-induced colonic motility as indicated by the stool pellet output (panel a) and colonic mucosal mucin content (panel b) in adult male Sprague-Dawley rats. Colon motility was decreased to 48% and 49% by diazepam and antalarmin, respectively. Colon mucin content was increased more than two-fold by antalarmin treatment. *P Ͻ 0.05. In freely moving animals, none of the drugs significantly caused any significant change in gastric ulceration, colonic mucin or defecation scores as compared to saline treatment. ) on struggling scores (panel a), plasma epinephrine (panel b) and norepinephrine (panel c) after exposure of adult male Sprague-Dawley rats to 4 h of immobilization stress. All drugs were injected in two full doses at −24 and −2 h of exposure to immobilization stress in the peritoneal cavity except for diazepam that was administered intramuscularly. Assays utilized trunk blood samples collected immediately after releasing the animals from the restrainers. *P Ͻ 0.05, **P Ͻ 0.01. Exposure to this stressor elevated plasma epinephrine (from 8.40 ± 2.22 to 21.11 ± 2.55 ng ml −1 , t = 3.76, P Ͻ 0.01 ) and increased plasma norepinephrine (from 5.45 ± 1.278 to 10.23 ± 0.849 ng ml −1 , t = 3.243, P Ͻ 0.01) as compared to freely moving animals. There was naturally no struggling behavior in freely moving subjects.
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both CRH and urocortin-induced colonic motor response. 43 The expression of the urocortin gene in the gastrointestinal tract has also been investigated using reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization histochemistry. PCR has demonstrated the presence of urocortin mRNA in the rat brain, duodenum, small intestine, and colon. By in situ hybridization, urocortin-containing cells are exclusively localized to the submucosal plexus and myenteric plexus in the duodenum, small intestine and colon. 77 More recently, urocortin and CRH-R1 mRNA have been detected in the human colonic mucosal as well. 78 Several lines of evidence have emerged to indicate bidirectional communication between brain and enteric CRH systems. CRH pathways have been traced between the rectum and the brainstem autonomic nuclei. 79 A major symptom in IBS is the exaggerated pain sensitivity to colon distension, which is correlated with psychological stress. 80 CRH released in the gastrointestinal mucosa from immune cells or enterochromaffin cells may play a role in the modulation of rectal afferent function as it decreases the thresholds and increases the intensity for the sensation of discomfort in response to distension. These findings are consistent with a dual effect of CRH on afferent pathways mediating perception of aversive rectal sensations in humans. 81 CRH also mediates the increase in locus coeruleus spontaneous discharge during colonic distension in rats. 82 Activation of the locus coeruleusnoradrenergic system during colon distension has been ) on adult male Sprague-Dawley rats' colon motility (as indicated by the stool pellet output: SPO) and mucin (indicated by the number of mucin-positive colonocytes %) in freely moving animals 4 h after the injections. *P Ͻ 0.05. The effects of intraperitoneal CRH were abolished by antalarmin pretreatment, but were not affected by vagotomy or sham-vagotomy. *P Ͻ 0.05 when compared to the CRH group.
suggested to serve as a cognitive limb of the peripheral parasympathetic response and to play a role in disorders characterized by comorbidity of intestinal and psychiatric symptoms, such as irritable bowel syndrome. 82 On the efferent side, CRH acts in the locus coeruleus to induce a long lasting stimulation of colonic transit and bowel discharge. 83 This mechanism of action may explain the known clinical efficacy of antidepressants in IBS. In this study only diazepam was effective in suppressing colonic responses to stress, perhaps via a suppressive effect on CRH secretion. By virtue of their actions on the GABA/benzodiazepine/chloride ionophore complex, benzodiazepines are potent inhibitors of CRH secretion. 84 Our findings here, however, should not be taken as indices of the efficacy of the drugs tested, because of their different doses and pharmacokinetic profiles. We have not tested our drugs after multiple administrations to ensure their reaching of the steady state, which is beyond the scope of this study. Thus failure of a drug to attenuate a given stressinduced endpoint does not exclude its potential efficacy if administered differently.
Even though antalarmin significantly attenuated adreno-medullary responses to stress as indicated by the reductions of plasma epinephrine and norepi- nephrine, no alteration of catecholamine secretion was found in response to antidepressants that also attenuated stress ulceration. This supports our previous notion that suppression of sympathoadrenal responses to stress may not account for the anti-ulcer effects of drugs, because sympathectomy actually enhances the ulcerogenic processes in response to stress. 55 Other studies have shown that neither adrenalectomy nor hypophysectomy prevent the response of the intestine to stress, suggesting that neither adrenal nor pituitaryderived factors are responsible for mediating the effects of stress on the gut. 4 Therefore, the weight of evidence supports the implication of primarily central mechanisms in the pathogenesis of stress ulceration, and largely peripheral mechanisms, presumably utilizing CRH-R1 in the gut, in the colonic responses to stress.
Taken together, we conclude that brain CRH-R1 exerts an important role in transforming psychological adversity into visceral damage at least in the stomach. Our data also indicate that gut CRH-R1 mediates colonic responses to stress. Novel nonpeptide CRH-R1 antagonists may therefore provide an optimal treatment for such gastrointestinal disorders associated with stress as stress ulcer and possibly other pathogenetically related conditions such as peptic ulcer and irritable bowel syndrome in humans.
